Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Dupilumab, a human monoclonal antibody against interleukin-4 receptor alpha, inhibits signaling of interleukin-4 and interleukin-13, type 2 cytokines that may be important drivers of atopic or allergic diseases such as atopic dermatitis. METHODS: In two randomized, placebo-controlled, phase 3 trials of identical design (SOLO 1 and SOLO 2), we enrolled adults with moderate-to-severe atopic dermatitis whose disease was inadequately controlled by topical treatment. Patients were randomly assigned in a 1:1:1 ratio to receive, for 16 weeks, subcutaneous dupilumab (300 mg) or placebo weekly or the same dose of dupilumab every other week alternating with placebo. The primary outcome was the proportion of patients who had both a score of 0 or 1 (clear or almost clear) on the Investigator's Global Assessment and a reduction of 2 points or more in that score from baseline at week 16. RESULTS: We enrolled 671 patients in SOLO 1 and 708 in SOLO 2. In SOLO 1, the primary outcome occurred in 85 patients (38%) who received dupilumab every other week and in 83 (37%) who received dupilumab weekly, as compared with 23 (10%) who received placebo (P<0.001 for both comparisons with placebo). The results were similar in SOLO 2, with the primary outcome occurring in 84 patients (36%) who received dupilumab every other week and in 87 (36%) who received dupilumab weekly, as compared with 20 (8%) who received placebo (P<0.001 for both comparisons). In addition, in the two trials, an improvement from baseline to week 16 of at least 75% on the Eczema Area and Severity Index was reported in significantly more patients who received each regimen of dupilumab than in patients who received placebo (P<0.001 for all comparisons). Dupilumab was also associated with improvement in other clinical end points, including reduction in pruritus and symptoms of anxiety or depression and improvement in quality of life. Injection-site reactions and conjunctivitis were more frequent in the dupilumab groups than in the placebo groups. CONCLUSIONS: In two phase 3 trials of identical design involving patients with atopic dermatitis, dupilumab improved the signs and symptoms of atopic dermatitis, including pruritus, symptoms of anxiety and depression, and quality of life, as compared with placebo. Trials of longer duration are needed to assess the long-term effectiveness and safety of dupilumab. (Funded by Sanofi and Regeneron Pharmaceuticals; SOLO 1 ClinicalTrials.gov number, NCT02277743 ; SOLO 2 ClinicalTrials.gov number, NCT02277769 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As neurons express receptors for IL-4 and IL-13, the early improvement of itch upon targeted therapy with dupilumab, tralokinumab or lebrikizumab supports the assumption of a direct effect of these drugs on nerve endings92,96,183.”
From Atopic dermatitis: an expanding therapeutic pipeline for a complex disease (2022) · cites this paper as [183]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Two phase 3 trials found dupilumab to significantly improve symptoms and quality of life in patients with AD compared to placebo [39].”
From Atopic dermatitis (2018) · cites this paper as [39]
The cited source says what the claim attributes to it.
In the citing paper
“Upadacitinib, a JAK inhibitor with proven efficacy in moderate-tosevere AD 30,31 , and dupilumab, an IL-4Rα antagonist that blocks IL-4/IL-13 signalling 32,33 , were selected.”
From Vascularized human skin assembloids model compartmental skin organization and immune responsiveness in vitro (2026) · cites this paper as [33]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Hospital Anxiety and Depression Scale
Zigmond, A. S., & Snaith, R. P. (1983) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1983.tb09716.x · Cited by 47,139
The validity of the Hospital Anxiety and Depression Scale
Bjelland, I., Dahl, A. A., Haug, T. T., & Neckelmann, D. (2002) · Journal of Psychosomatic Research · doi:10.1016/s0022-3999(01)00296-3 · Cited by 9,779
Severity Scoring of Atopic Dermatitis: The SCORAD Index
(2009) · Dermatology · doi:10.1159/000247298 · Cited by 2,273
Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
Beck, L. A., Thaçi, D., Hamilton, J. D., Graham, N. M., Bieber, T., Rocklin, R., Ming, J. E., Ren, H., Kao, R., Simpson, E., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314768 · Cited by 1,421
Self-citationDupilumab in Persistent Asthma with Elevated Eosinophil Levels
Wenzel, S., Ford, L., Pearlman, D., Spector, S., Sher, L., Skobieranda, F., Wang, L., Kirkesseli, S., Rocklin, R., Bock, B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304048 · Cited by 1,320
Self-citationGuidelines of care for the management of atopic dermatitis
Eichenfield, L. F., Tom, W. L., Berger, T. G., Krol, A., Paller, A. S., Schwarzenberger, K., Bergman, J. N., Chamlin, S. L., Cohen, D. E., Cooper, K. D., et al. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.03.023 · Cited by 1,224
Self-citationThe eczema area and severity index (EASI): assessment of reliability in atopic dermatitis
Hanifin, J. M., Thurston, M., Omoto, M., Cherill, R., Tofte, S. J., Graeber, M., & Evaluator Group, T. E. (2001) · Experimental Dermatology · doi:10.1034/j.1600-0625.2001.100102.x · Cited by 1,200
Atopic dermatitis: a disease of altered skin barrier and immune dysregulation
Boguniewicz, M., & Leung, D. Y. M. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2011.01027.x · Cited by 1,073
Wenzel, S., Castro, M., Corren, J., Maspero, J., Wang, L., Zhang, B., Pirozzi, G., Sutherland, E. R., Evans, R. R., Joish, V. N., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30307-5 · Cited by 985
Self-citationGittler, J. K., Shemer, A., Suárez-Fariñas, M., Fuentes-Duculan, J., Gulewicz, K. J., Wang, C. Q. F., Mitsui, H., Cardinale, I., de Guzman Strong, C., Krueger, J. G., et al. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.07.012 · Cited by 981
Self-citation
Cited by
Items 901–1,000 of 1,002
IGAxBSA composite for assessing disease severity and response in patients with atopic dermatitis*
Paller, A. S., Tan, J. K. L., Bagel, J., Rossi, A. B., Shumel, B. S., Zhang, H., & Abramova, A. (2021) · British Journal of Dermatology · doi:10.1111/bjd.20872 · Cited by 17
The emerging role of skin microbiome in atopic dermatitis and its clinical implication
Stalder, J. ‐., Fluhr, J. W., Foster, T., Glatz, M., & Proksch, E. (2018) · Journal of Dermatological Treatment · doi:10.1080/09546634.2018.1516030 · Cited by 17
The emerging role of neuroimmune interactions in atopic dermatitis and itch
Fan, J. C., & Mishra, S. K. (2021) · FEBS Journal · doi:10.1111/febs.15860 · Cited by 19
Raster-scanning optoacoustic mesoscopy biomarkers for atopic dermatitis skin lesions
Nau, T., Schönmann, C., Hindelang, B., Riobó, L. M., Doll, A., Schneider, S., Englert, L., He, H., Biedermann, T., Darsow, U. G., et al. (2023) · Photoacoustics · doi:10.1016/j.pacs.2023.100513 · Cited by 22
“significant improvement of visible signs and subjective symptoms of AD [5].”
BackgroundPatra, V., Woltsche, N., Čerpes, U., Bokanovic, D., Repelnig, M., Joshi, A. A., Perchthaler, I., Fischl, M., Vocanson, M., Bordag, N., et al. (2023) · Ophthalmology Science · doi:10.1016/j.xops.2023.100340 · Cited by 17
Shim, K., Park, M., Yang, W., Lee, H., Kim, S., Choo, B.-K., Chae, S., Kim, H.-K., Kim, T. S., & Kim, K.-M. (2023) · Antioxidants · doi:10.3390/antiox12061267 · Cited by 16
Mental health in patients affected by atopic dermatitis: which effects of treatment with dupilumab?
Ferrucci, S. M., Tavecchio, S., Nicolini, G., Angileri, L., Ceresa, A., Tordello, G. D., Berti, E., Marzano, A. V., & Buoli, M. (2023) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000511 · Cited by 17
Schmid‐Grendelmeier, P., Gooderham, M., Hartmann, K., Konstantinou, G. Ν., Fellmann, M., Koulias, C., Clibborn, C., Biswas, P., & Brunner, P. M. (2023) · Allergy · doi:10.1111/all.15952 · Cited by 18
“…observed in clinical and real-world studies of patients with moderate-to-severe AD treated with the systemic IL-4 receptor inhibitor dupilumab 32,34–36 and were associated with the presence of conjunctivitis or food allergies at baseline in a retrospective, observational study of patients…”
BackgroundMusters, A. H., van Lookeren, F. L., van der Gang, L. F., Middelkamp-Hup, M. A., Bosma, A. L., Jessurun, N. T., Lapeere, H., Nguyen, A. L., Ouwerkerk, W., Schepper, S. D., et al. (2023) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.19643 · Cited by 20
“33–35 However, studies often do not specify the type of conjunctivitis.”
BackgroundTietz, J., Gunde, T., Warmuth, S., Weinert, C., Brock, M., Simonin, A., Hess, C., Johansson, M., Spiga, F., Muntwiler, S., et al. (2024) · JID Innovations · doi:10.1016/j.xjidi.2024.100258 · Cited by 16
Dupilumab Reduces Exacerbations Independent of Changes in Biomarkers in Moderate-to-Severe Asthma
Pavord, I. D., Casale, T. B., Corren, J., FitzGerald, M. J., Deniz, Y. M., Altincatal, A., Gall, R., Pandit‐Abid, N., Radwan, A., Jacob-Nara, J. A., et al. (2024) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2024.03.031 · Cited by 18
Ferrucci, S., Tavecchio, S., Maronese, C. A., Balato, A., Brizzi, E. V. D., Ortoncelli, M., Ribero, S., Girolomoni, G., Maurelli, M., Fortina, A. B., et al. (2024) · Clinical and Experimental Dermatology · doi:10.1093/ced/llae208 · Cited by 16
Real-World Evidence of Tralokinumab Effectiveness and Safety: A Systematic Review and Meta-analysis
Rønnstad, A. T. M., Bunick, C. G., Chovatiya, R., Kamata, M., Nielsen, M., Isufi, D., Thomsen, S. F., Vestergaard, C., Wollenberg, A., Egeberg, A., et al. (2025) · American Journal of Clinical Dermatology · doi:10.1007/s40257-025-00927-x · Cited by 18
Self-citationManagement of Atopic Dermatitis in Japan
Saeki, H. (2017) · Journal of Nippon Medical School · doi:10.1272/jnms.84.2 · Cited by 17
Endotypes in allergic diseases
Agache, I. O., & Rogozea, L. M. (2018) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0000000000000434 · Cited by 18
Rook, A. H., Rook, K. A., & Lewis, D. J. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-55617-4_8 · Cited by 17
Toron, F., Neary, M. P., Smith, T. W., Gruben, D. C., Romero, W., Cha, A., Patel, K., Vasileva, S. Z., & Ameen, M. (2021) · Dermatology and Therapy · doi:10.1007/s13555-021-00519-7 · Cited by 18
“associated with a substantial increase in the frequency of comorbidities, which further associate with detrimental impact on quality of life and productivity loss [27, 63].”
BackgroundChronic itch in African Americans: an unmet need
Ingrasci, G., El-Kashlan, N., Alexis, A. F., & Yosipovitch, G. (2021) · Archives of Dermatological Research · doi:10.1007/s00403-021-02255-6 · Cited by 16
Ocular surface disorders associated with the use of dupilumab based on WHO VigiBase
Park, S., Lee, J. H., Park, J. H., Park, S. H., Park, S. Y., Jung, Y. W., & Choi, S. A. (2021) · Scientific Reports · doi:10.1038/s41598-021-93750-3 · Cited by 22
A Review of the Immunologic Pathways Involved in Bullous Pemphigoid and Novel Therapeutic Targets
Afarideh, M., Borucki, R., & Werth, V. P. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11102856 · Cited by 16
“The medication was FDA-approved for atopic dermatitis in 2017 and is currently being studied in a number of diseases that involve the type 2 inflammatory pathway, including BP [77].”
BackgroundFuture trends in the treatment of atopic dermatitis
Igawa, K. (2019) · Immunological Medicine · doi:10.1080/25785826.2019.1628467 · Cited by 19
“were reportedly good [26], and based on those results dupilumab was approved for AD treatment in Europe, the USA and Japan during 2017 and 2018.”
BackgroundRosso, J. Q. D. (2019) · Europe PMC (PubMed Central) · Cited by 16
Lebrikizumab for Moderate-to-Severe Atopic Dermatitis
Smith, B., Engel, P., & Wu, J. J. (2023) · New England Journal of Medicine · doi:10.1056/nejmc2304782 · Cited by 17
Honstein, T., & Werfel, T. (2020) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0000000000000652 · Cited by 17
“The key studies showed efficacy of a reduction of the skin score EASI by 75% (’EASI75’) after 16 weeks [5], respectively 1 year [6] in approximately two-thirds of the study patients.”
BackgroundManagement of dupilumab-associated ocular surface diseases in atopic dermatitis patients
Guex‐Crosier, Y., Di‐Lucca, J., Häusermann, P., Laffitte, E., Saulīte, I., Schmid‐Grendelmeier, P., Schürch, K., Thormann, K., & Simon, D. (2021) · Swiss Medical Weekly · doi:10.4414/smw.2021.w30020 · Cited by 21
Ghazal, S., Ridha, Z., D’Aguanno, K., Nassim, D., Quaiattini, A., Netchiporouk, E., Poulin, Y. P., Kalia, S., Marcoux, D., Piguet, V., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.821871 · Cited by 17
Self-citationAchten, R., Thijs, J. L., van der Wal, M., van Luijk, C., van Luin, M., Amrani, M. E., Knol, E. F., Delemarre, E. M., Jager, C. F. D. H., de Graaf, M., et al. (2023) · Clinical and Translational Allergy · doi:10.1002/clt2.12221 · Cited by 14
“It is also hypothesised that DAOSD incidence may decrease in patients with higher serum dupilumab concentrations, and that local under‐treatment of dupilumab in the eyes might play a role in the development of DAOSD.(6,9) At this moment, the exact patho‐mechanism of DAOSD remains unclear.”
BackgroundResultInfluentialChiricozzi, A., Nardo, L. D., Gori, N., Antonelli, F., Pinto, L., Cuffaro, G., Piro, G., Savino, G., Tortora, G., & Peris, K. (2023) · Experimental Dermatology · doi:10.1111/exd.14859 · Cited by 15
Navarro‐Triviño, F. J., Galán‐Gutiérrez, M., Hita, J. C. A., Ruíz‐Villaverde, R., Dominguez‐Cruz, J. J., & Rodríguez, J. (2023) · Dermatitis · doi:10.1089/derm.2023.0220 · Cited by 15
“11 Several studies in real world practice 12–17 and a phase II clinical trial 18 have investigated the use of dupilumab in HFE shedding light on its effectiveness in reducing symptoms and improving overall disease control.”
Pezzolo, E., Ortoncelli, M., Ferrucci, S. M., Guanti, M. B., Schena, D., Napolitano, M., Rossi, M., Foti, C., D’Amico, D., Amoruso, G. F., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13020553 · Cited by 18
“Phase 3 randomized clinical trials (RCTs) and real-world studies have proven the long-term effectiveness and safety of dupilumab and tralokinumab for the management of moderate-to-severe AD [7–14].”
BackgroundCaminati, M., Maule, M., Benoni, R., Bagnasco, D., Beghé, B., Braido, F., Brussino, L., Cameli, P., Candeliere, M. G., Carpagnano, G. E., et al. (2024) · Biomedicines · doi:10.3390/biomedicines12020390 · Cited by 16
Dupilumab impact on psychiatric and sleep disorder risk reduction in atopic dermatitis
Lin, T., Fan, Y., Fan, K.-S., Juan, C., Chen, Y., & Wu, C. (2024) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2024.11.016 · Cited by 16
Awosika, O., Kim, L. S., Mazhar, M., Rengifo‐Pardo, M., & Ehrlich, A. (2018) · Clinical Cosmetic and Investigational Dermatology · doi:10.2147/ccid.s123329 · Cited by 20
“30 Overall, these results suggest that IL-4 and IL-13 are important mediators in the pathogenesis and morbidity of AD.”
InfluentialDupilumab para el tratamiento de la dermatitis atópica
Ferreira, S., & Torres, T. R. (2018) · Actas Dermo-Sifiliográficas · doi:10.1016/j.ad.2017.10.012 · Cited by 22
“…(anti-IL-22), secukinumab (anti-IL-17), omalizumab (receptor de la inmunoglobulina E anti-Fc), apremilast (anti-PDE4) e inhibidores de la JAK tofacitinib y baricitinib, en estudios en curso de los que todavía no hay resultados; y 4) tocili-zumab (receptor de la IL-6/antagonista de la IL-6R).”
Monoclonal antibodies for the treatment of atopic dermatitis
Renert‐Yuval, Y., & Guttman‐Yassky, E. (2018) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0000000000000455 · Cited by 18
“Tralokinumab and lebrikizumab are IgG4 fully humanized monoclonal antibodies specifically antagonizing IL-13.”
BackgroundInfluentialSelf-citationMepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis
Ennis, D., Lee, J. K., & Pagnoux, C. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1623875 · Cited by 17
Mareschal, A., Puzenat, E., & Aubin, F. (2019) · Acta Dermato Venereologica · doi:10.2340/00015555-3368 · Cited by 15
Lansang, P., Lam, J. M., Marcoux, D., Prajapati, V. H., Spring, S., & Lara‐Corrales, I. (2019) · Journal of Cutaneous Medicine and Surgery · doi:10.1177/1203475419882647 · Cited by 15
Psoriasis bei Dupilumab-behandeltem atopischem Ekzem
Senner, S., Eicher, L., ASZODI, N., Prinz, J. C., French, L. E., & Wollenberg, A. (2020) · Der Hautarzt · doi:10.1007/s00105-020-04565-8 · Cited by 20
Self-citationDupilumab: One therapy to treat multiple atopic diseases
Bawany, F., Franco, A. I., & Beck, L. A. (2020) · JAAD Case Reports · doi:10.1016/j.jdcr.2020.08.036 · Cited by 15
“It is not uncommon for AD patients to have a history of multiple allergic conditions; it is less common to have all of them coexisting (ie, active) concurrently.(4-6) To our knowledge, this is the first case report of a pediatric AD patient with multiple comorbid allergic conditions who experienced objective improveme…”
BackgroundSelf-citationImmunotherapies in cutaneous pathologies: an overview
Baylet, A., Laclaverie, M., Marchand, L., Bordes, S., Closs, B., & Delpy, L. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.10.023 · Cited by 16
Dupilumab and conjunctivitis: a case series of twenty patients
Calabrese, G., Gambardella, A., Licata, G., Brizzi, E. V. D., Alfano, R., & Argenziano, G. (2021) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.17210 · Cited by 15
Effectiveness of ustekinumab in patients with atopic dermatitis: analysis of real-world evidence
Husein‐ElAhmed, H., & Steinhoff, M. S. (2021) · Journal of Dermatological Treatment · doi:10.1080/09546634.2021.1914315 · Cited by 17
Kim, B., Silverberg, J. I., Ständer, S., Yosipovitch, G., Simpson, E. L., DiBonaventura, M., Kerkmann, U., Farooqui, S. A., Biswas, P., Valdez, H., et al. (2021) · Dermatitis · doi:10.1097/der.0000000000000770 · Cited by 16
“Nevertheless, fewer than 40% of dupilumab-treated patients achieve IGA and/or PP-NRS4 responses at week 16.(26) In addition, the majority of itch improvement (as measured by PP-NRS4) is observed after week 2, with much of the improvement happening after week 4.”
BackgroundInfluentialSelf-citationDupilumab for STAT3-Hyper-IgE Syndrome With Refractory Intestinal Complication
Lu, C., Lee, W., & Chung, W. (2021) · PEDIATRICS · doi:10.1542/peds.2021-050351 · Cited by 16
Novel systemic treatments in atopic dermatitis: Are there sex differences?
Tuttle, K. L., Forman, J., & Beck, L. A. (2021) · International Journal of Women’s Dermatology · doi:10.1016/j.ijwd.2021.10.002 · Cited by 17
“The adverse effects of dupilumab included injection site reactions and a range of ocular complaints (including sicca, conjunctivitis, and blepharitis; Beck et al., 2020 ; Blauveltet al., 2017 ; Paller et al., 2020 ; Simpson et al., 2016 ; 2020 ).”
BackgroundSelf-citationAtopic dermatitisReview of comorbidities and therapeutics
Appiah, M., Haft, M. A., Kleinman, E. P., Laborada, J., Lee, S., Loop, L., Geng, B., & Eichenfield, L. F. (2022) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2022.05.015 · Cited by 15
Heeb, L. E. M., & Boyman, O. (2022) · Allergy · doi:10.1111/all.15576 · Cited by 15
Use of oral immunosuppressive drugs in the treatment of atopic dermatitis in the Netherlands
Garritsen, F. M., van den Heuvel, J. M., Bruijnzeel-Koomen, C. A. F. M., der Zee, A. H. M., van den Broek, M. P. H., & de Bruin-Weller, M. S. (2018) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.14896 · Cited by 15
Holgate, S. T., Walker, S. M., West, B., & Boycott, K. (2019) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2018.10.013 · Cited by 18
Thyssen, J. P., Rosmarin, D. M., Costanzo, A., Warren, R. B., Chu, C., Chovatiya, R., Ladizinski, B., Hu, X., Liu, Y., Calimlim, B., et al. (2024) · Dermatology · doi:10.1159/000542275 · Cited by 23
“…DUPI, dupilumab. rosacea, allergic contact dermatitis, alcohol-induced facial fl ushing, and drug-induced photosensitivity reaction in the pathophysiology of this paradoxical head and neck erythema, but results were not conclusive and further research on pathophysiology is needed [9, 11].”
Brief Academic Review and Clinical Practice Guidelines for Pediatric Atopic Dermatitis
Yang, Y. B., Gohari, A., & Lam, J. M. (2020) · Current Pediatric Reviews · doi:10.2174/1573396316999200820163434 · Cited by 16
Armstrong, A. W., Blauvelt, A., Simpson, E. L., Smith, C. H., Herranz, P., Kataoka, Y., Seo, S. J., Ferrucci, S. M., Chao, J., Chen, Z., et al. (2021) · Dermatology and Therapy · doi:10.1007/s13555-021-00643-4 · Cited by 15
“Baseline demographics (Table 1) were similar to those reported in the parent studies [8, 9]; however, the patients not achieving EASI-75 or IGA 0 or 1 in the initial 16 weeks of dupilumab treatment had a more severe disease profile than those who did achieve those endpoints (Table 2).”
MethodResultSelf-citationNakahara, T., Izuhara, K., Onozuka, D., Saeki, H., Nunomura, S., Takenaka, M., Matsumoto, M., Kataoka, Y., Fujimoto, R., Kaneko, S., et al. (2022) · Clinical & Experimental Allergy · doi:10.1111/cea.14267 · Cited by 14
“Secondary end- points were (1) the association between baseline levels of 19 biomarkers and % change from baseline of POEM at 16 w; (2) the association between baseline levels of 19 biomarkers and % change from baseline of pruritus- NRS at 16 w; (3) the association between baseline levels of 19 biomarkers and % change…”
BackgroundSelf-citationOrfali, R. L., Lorenzini, D., Bressan, A. L., Tanaka, A. A., de Cerqueira, A. M. M., Hirayama, A. L. D. S., Ramos, A. M. C., Proença, C. C., Silva, C. M. R., Laczynski, C. M. M., et al. (2023) · Anais Brasileiros de Dermatologia · doi:10.1016/j.abd.2023.04.003 · Cited by 46
Leyva-Castillo, J. M., McGurk, A. I., Strakosha, M., Vega‐Mendoza, D., Smith, S. E. M., Stafstrom, K., Elkins, M., Chou, J. S., Wang, Y., & Geha, R. S. (2023) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2023.05.025 · Cited by 17
Wynne, C. J., Cole, A., Lemech, C., Wang, G., Zhang, Y., Chen, B., Wang, M. M., Li, B., Xia, M., & Sinclair, R. D. (2023) · Dermatology and Therapy · doi:10.1007/s13555-023-01010-1 · Cited by 15
“The proportion of subjects who achieved EASI 50 and EASI 75 was higher in the AK120 treatment groups (64.5% [20/31] and 35.5% [11/31], respectively), than than in the placebo group (12.5% [1/8] and 0, respectively).”
BackgroundInfluentialRamos, F. J. M., González-Delgado, V. A., Motilla, J. M. S., Pascual, M. G., Puchades, A. M., & Alarcón, S. S. (2023) · Australasian Journal of Dermatology · doi:10.1111/ajd.14164 · Cited by 18
Dupilumab-associated inflammatory arthritis: a literature review
Napolitano, M., Ruggiero, A., & Patruno, C. (2023) · Clinical and Experimental Dermatology · doi:10.1093/ced/llad390 · Cited by 17
Schaarschmidt, M., Kromer, D., Wellmann, P., Peitsch, W. K., & Kromer, C. (2024) · Journal of Dermatological Treatment · doi:10.1080/09546634.2024.2308682 · Cited by 16
“The IL-4 receptor antibody dupilumab was approved for treatment of moderate-to-severe AD in the United States (US) and in the European Union (EU) in 2017, the IL-13 antibody traloki-numab in 2021 and the IL-13 antibody lebrikizumab very recently in 2023 (10–12).”
Kido‐Nakahara, M., Onozuka, D., Izuhara, K., Saeki, H., Nunomura, S., Takenaka, M., Matsumoto, M., Kataoka, Y., Fujimoto, R., Kaneko, S., et al. (2024) · Journal of Allergy and Clinical Immunology Global · doi:10.1016/j.jacig.2024.100317 · Cited by 16
Self-citationKido‐Nakahara, M., Chiba, T., Mizusawa, Y., Higashi, Y., Ibusuki, A., Igawa, S., Murakami, Y., Matsunaka, H., Fuyuno, Y., Tsuji, G., et al. (2024) · Allergology International · doi:10.1016/j.alit.2024.08.010 · Cited by 15
Immunogenicity of dupilumab in adult and pediatric patients with atopic dermatitis
Kamal, M. A., Kosloski, M. P., Lai, C., Partridge, M. A. K., Rajadhyaksha, M., Kanamaluru, V., Bansal, A., Shabbir, A., Shumel, B. S., Ardeleanu, M., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1466372 · Cited by 20
Self-citationKridin, K., Abdelghaffar, M., Bieber, K., Thaçi, D., & Ludwig, R. J. (2025) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.20724 · Cited by 14
“9,10 9–11 Based on these placebo-controlled trials, dupilumab was associated with a decreased risk of severe systemic infection and bacterial cutaneous infections, but a slightly elevated risk of herpes simplex infections.”
Viswanathan, R. K., & Busse, W. (2018) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0037-1606218 · Cited by 15
Handa, Y., Ugajin, T., Igawa, K., Hamamoto, H., Kobayashi, K., Komatsuno, T., Yamamoto, T., Kawahara, K., & Yokozeki, H. (2019) · Allergology International · doi:10.1016/j.alit.2018.12.011 · Cited by 14
Matthias, J., & Zielinski, C. E. (2019) · European Journal of Immunology · doi:10.1002/eji.201848011 · Cited by 15
New Insights and Treatments in Atopic Dermatitis
Saini, S., & Pansare, M. V. (2021) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2021.07.005 · Cited by 17
Dupilumab Treatment Reduces Hospitalizations in Adults With Moderate-to-Severe Atopic Dermatitis
Silverberg, J. I., Rubini, N. P. M., Pires, M. C., Rossi, A. B., Zhang, A., Chen, Z., Levit, N. A., Chao, J., Shumel, B., & Bagousse, G. B.-L. (2022) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2021.11.034 · Cited by 14
Self-citationBreak on Through: The Role of Innate Immunity and Barrier Defence in Atopic Dermatitis and Psoriasis
Hawerkamp, H. C., Fahy, C. M. R., Fallon, P. G., & Schwartz, C. (2022) · Skin Health and Disease · doi:10.1002/ski2.99 · Cited by 16
Model-Based Meta-Analysis to Optimize Staphylococcus aureus‒Targeted Therapies for Atopic Dermatitis
Miyano, T., Irvine, A. D., & Tanaka, R. J. (2022) · JID Innovations · doi:10.1016/j.xjidi.2022.100110 · Cited by 15
“The responder rates for dupilumab were 44‒69% (Blauvelt et al., 2017; Simpson et al., 2016b) for Eczema Area and Severity Index (EASI) 75 (75% reduction in the EASI score) (Hanifin et al., 2001; Schram et al., 2012), leaving a significant proportion of dupilumab poor responders.”
BackgroundMethodInfluentialde Bruin-Weller, M. S., Serra‐Baldrich, E., Barbarot, S., Grond, S., Schuster, C., Petto, H., Capron, J.-P., Raibouaa, A., & Werfel, T. (2022) · Dermatology and Therapy · doi:10.1007/s13555-022-00734-w · Cited by 15
Gelato, F., Mastorino, L., Quaglino, P., Cavaliere, G., Ortoncelli, M., & Ribero, S. (2023) · Dermatitis · doi:10.1089/derm.2022.0063 · Cited by 14
Kiefer, S., König, A., Gerger, V., Rummenigge, C., Müller, A. C., Jung, T., Frank, A., Tassopoulos, G., Laurent, E., Kaufmann, R., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12031175 · Cited by 17
Topical E6005/RVT-501, a novel phosphodiesterase 4 inhibitor, for the treatment of atopic dermatitis
Furue, M., Kadono, T., Tsuji, G., & Nakahara, T. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1397626 · Cited by 14
T helper type 2 signatures in atopic dermatitis
Furue, M. (2018) · Journal of Cutaneous Immunology and Allergy · doi:10.1002/cia2.12023 · Cited by 16
“In parallel, recent clinical trials have revealed that blockade of IL‐4/IL‐ 13 signaling by anti–IL‐4 receptor α antibody dupilumab significantly improves atopic inflammation.(45,114) In addition, the anti–IL‐”
BackgroundImmunomodulators in chronic rhinosinusitis
Lavigne, P., & Lee, S. E. (2018) · World Journal of Otorhinolaryngology - Head and Neck Surgery · doi:10.1016/j.wjorl.2018.09.002 · Cited by 22
“Dupilumab, with the tradename Dupixent was approved in 2017 for the treatment of moderate-to-severeatopic dermatitis and is also investigated for persistent, uncontrolled asthma.(32,33) These studies suggest the importance of IL-4 and IL-13 in chronic inflammatory disorders such as asthma, atopic dermatitis, and CRSwN…”
BackgroundTakeuchi, S., Furusyo, N., Ono, J., Azuma, Y., Takemura, M., Esaki, H., Yamamura, K., Mitamura, Y., Tsuji, G., Mari, O. D. A., et al. (2019) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2019.07.005 · Cited by 15
Brøgger, P., Blom, L. H., Simonsen, S., Thyssen, J. P., & Skov, L. (2019) · Scandinavian Journal of Immunology · doi:10.1111/sji.12835 · Cited by 14
Targeted biologic therapy for asthma
Hynes, G., & Pavord, I. D. (2020) · British Medical Bulletin · doi:10.1093/bmb/ldaa004 · Cited by 16
Georgakopoulos, J. R., & Yeung, J. (2020) · Journal of Cutaneous Medicine and Surgery · doi:10.1177/1203475420930223 · Cited by 14
Use of dupilumab in a patient with atopic dermatitis, severe asthma, and HIV infection
Brodská, P., Panzner, P., Sedláček, D., Teřl, M., & Cetkovská, P. (2020) · Dermatologic Therapy · doi:10.1111/dth.14159 · Cited by 14
“Pruritus is the essential feature of AD.”
BackgroundResultInfluentialThe Posology of Dupilumab in Pediatric Patients With Atopic Dermatitis
Kamal, M. A., Kovalenko, P., Kosloski, M. P., Srinivasan, K., Zhang, Y. C., Rajadhyaksha, M., Lai, C., Kanamaluru, V., Xu, C. R., Sun, X., et al. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2366 · Cited by 17
Self-citationKeeping an eye on the ocular problems in dupilumab clinical trials
Chu, C. (2019) · British Journal of Dermatology · doi:10.1111/bjd.18255 · Cited by 14
A basophil-fibroblast pro-inflammatory axis fuels type 2 skin inflammation
Imanishi, I., Gill, R., Wilder, A., Restrepo, P., Nair, A., Cho, I., Krueger, J. G., Guttman‐Yassky, E., Kim, B., & Ji, A. L. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116114 · Cited by 16
“This axis appears to be conserved in a canonical human type 2 inflammatory skin disease, AD, highlighting our translational relevance.”
Self-citationEGFR-STAT1 pathway drives fibrosis initiation in fibroinflammatory skin diseases
Odell, A. V., Newton, N. M., Eisenstein, A. S., Micevic, G., Flavell, R. A., & Odell, I. D. (2025) · Nature Communications · doi:10.1038/s41467-025-64648-9 · Cited by 17
Onychodystrophy associated with dupilumab therapy for atopic dermatitis
Zubek, A., & Vesely, M. D. (2020) · JAAD Case Reports · doi:10.1016/j.jdcr.2020.10.024 · Cited by 13
“Treatment of AD by dupilumab has been shown to be efficacious, with long-term benefit.(2) Unique dupilumab-associated side effects in patients with AD have been reported, including conjunctivitis(2) and head and neck dermatitis(3) caused by unknown mechanisms.”
BackgroundBiologics for Asthma and Allergic Skin Diseases in Children
Keyser, H. H. D., Chipps, B. E., Dinakar, C., & MEDICINE, S. O. A. A. I. A. S. O. P. P. A. S. (2021) · PEDIATRICS · doi:10.1542/peds.2021-054270 · Cited by 13
Modern Interventions for Pediatric Atopic Dermatitis: An Updated Pharmacologic Approach
Kondratuk, K. E., Netravali, I. A., & Castelo‐Soccio, L. A. (2022) · Dermatology and Therapy · doi:10.1007/s13555-022-00868-x · Cited by 18
“Dupilumab-related adverse events included conjunctivitis, transient eosinophilia, and injection site reactions [44, 45, 47, 49, 50].”
BackgroundWang, A., Zhou, Y., Luo, Y., Gao, Y., Chen, J., Li, W., Luo, X., & Yao, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1160710 · Cited by 14
A multimodal sensing ring for quantification of scratch intensity
Padmanabha, A., Choudhary, S., Majidi, C., & Erickson, Z. (2023) · Communications Medicine · doi:10.1038/s43856-023-00345-2 · Cited by 14
“For reference, in clinical trials, studies often use a change of 4 units on a subjective, patient reported version of the 0-10 scale as the minimal clinically important difference [22, 23].”
MethodCaminiti, L., Galletta, F., Randazzese, S. F., Barraco, P., Passanisi, S., Gambadauro, A., Crisafulli, G., Valenzise, M., & Manti, S. (2024) · Children · doi:10.3390/children11020170 · Cited by 13
“Real-world studies with longer-term follow-ups and larger sample sizes are needed to better determine the efficacy and safety of biologics in children.”
BackgroundReguiaï, Z., Bécherel, P., Perrot, J., Boulard, C., Fougerousse, A. C., Bégon, E., Badaoui, A., Poreaux, C., Parier, J., Liegeon, A., et al. (2024) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.20233 · Cited by 13
Interleukin Profiling in Atopic Dermatitis and Chronic Nodular Prurigo
Wiegmann, H., Renkhold, L., Zeidler, C., Agelopoulos, K., & Ständer, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158445 · Cited by 13
“Targeting IL-4 receptor (IL-4R) signaling pathways emerges as a promising therapeutic avenue that offers hope for individuals dealing with the persistent pruritus and cutaneous inflammation characteristics of AD [9].”
BackgroundBlauvelt, A., Reckleff, J., Zhao, Y., Clark, M., Kosa, K., Harris, N., Esfandiari, E., Martin, S. A., Whalley, D., & Guttman‐Yassky, E. (2024) · British Journal of Dermatology · doi:10.1093/bjd/ljae346 · Cited by 13
“%) reported that AD Skin Pain NRS (1.0) item 2A was clearer than item 2B [‘I think that 2A is easier because it asks you to pinpoint a specific moment’ (IDI 15)], and 6 of 26 participants (23”
InfluentialSelf-citationRossi, M., Ferrucci, S. M., Calzavara‐Pinton, P., Marzano, A. V., Peris, K., Nicoli, E., Moretti, D., & Chiricozzi, A. (2024) · Advances in Therapy · doi:10.1007/s12325-024-03052-z · Cited by 15
Carr, S., Pratt, R., White, F., & Watson, W. T. A. (2024) · Allergy Asthma and Clinical Immunology · doi:10.1186/s13223-024-00927-2 · Cited by 23
Drugs on the Horizon for Chronic Pruritus
McEwen, M. W., Fite, E. M., Yosipovitch, G., & Patel, T. S. (2018) · Dermatologic Clinics · doi:10.1016/j.det.2018.02.016 · Cited by 13
Dupilumab for the treatment of adolescents with atopic dermatitis
Senner, S., Seegräber, M., Frey, S., Kendziora, B., Eicher, L., & Wollenberg, A. (2020) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2020.1801420 · Cited by 14
Self-citationBeck, L. A., Silverberg, J. I., Simpson, E. L., Yosipovitch, G., Eckert, L., Guillemin, I., Chen, Z., Ardeleanu, M., Plaum, S., Graham, N. M. H., et al. (2020) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.16865 · Cited by 15
Self-citation
Metadata
- Authors
- Simpson, E. L., Bieber, T., Guttman-Yassky, E., Beck, L. A., Blauvelt, A., Cork, M. J., Silverberg, J. I., Deleuran, M., Kataoka, Y., Lacour, J.-P., Kingo, K., Worm, M., Poulin, Y., Wollenberg, A., Soo, Y., Graham, N. M. H., Pirozzi, G., Akinlade, B., Staudinger, H., Mastey, V., Eckert, L., Gadkari, A., Stahl, N., Yancopoulos, G. D., & Ardeleanu, M.
- Affiliations
- University of Bonn (DE)
- Northwestern University (US)
- ORCID
- Simpson, Eric L.
- Bieber, Thomas
- Beck, Lisa A.
- Blauvelt, Andrew
- Cork, Michael J.
- Silverberg, Jonathan I.
- Deleuran, Mette
- Kataoka, Yoko
- Lacour, Jean-Philippe
- Kingo, Külli
- Worm, Margitta
- Poulin, Yves
- Wollenberg, Andreas
- Soo, Yuhwen
- Graham, Neil M.H.
- Pirozzi, Gianluca
- Akinlade, Bolanle
- Staudinger, Heribert
- Eckert, Laurent
- Stahl, Neil
- Ardeleanu, Marius
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-12-15
- Volume
- 375
- Issue
- 24
- Pages
- 2335-2348
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2524051065
- Cited by
- 2,110
- References
- 38
- Citations by year
- 2026: 183 · 2025: 219 · 2024: 227 · 2023: 239 · 2022: 218 · 2021: 238 · 2020: 244 · 2019: 236 · 2018: 160 · 2017: 130 · 2016: 8
- FWCI
- 211.58
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion, other-oa)
- Scopus (Elsevier) (submittedVersion)
- Topics
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
- Keywords
- ab, atopic dermatitis, IL-4 receptor alpha, IL-13, IL-4, type 2 cytokines, monoclonal antibodies, subcutaneous administration, dosing frequency, Investigator's Global Assessment, Eczema Area and Severity Index, pruritus, injection site reactions, conjunctivitis, quality of life
- MeSH terms
- Adult, Anti-Inflammatory Agents, Antibodies, Monoclonal, Dermatitis, Atopic, Double-Blind Method, Female, Humans, Injections, Subcutaneous, Male, Middle Aged, Nasopharyngitis, Pruritus, Quality of Life, Interleukin-4, Interleukin-13, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.